한빛사논문
Sung-Min Hwang, Yu-Jin Ha, Gi-Bang Koo, Hyun-Jin Noh, A-Yeon Lee, Byeong-Ju Kim, Sun Mi Hong, Michael J. Morgan, Seong-il Eyun, Dakeun Lee, Jae-Seok Roe, Youngsoo Lee, and You-Sun Kim*
S.-M. Hwang, Y.-J. Ha, G.-B. Koo, H.-J. Noh, A-Y. Lee, B.-J. Kim, S. M. Hong, Y.-S. Kim
Department of Biochemistry and Molecular Biology
Ajou University School of Medicine
164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499, Republic of
Korea
S.-M. Hwang
Sandra and Edward Meyer Cancer Center and Department of Obstetrics
and Gynecology
Weill Cornell Medicine
New York, NY 10065, USA
Y.-J. Ha, G.-B. Koo, H.-J. Noh, A-Y. Lee, B.-J. Kim, Y.-S. Kim
Department of Biomedical Sciences
Graduate School of Ajou University
164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499, Republic of
Korea
M. J. Morgan
Department of Natural Sciences
Northeastern State University
Tahlequah, OK 74464, USA
S.-il Eyun
Department of Life Science
Chung-Ang University
Seoul 06973, Republic of Korea
D. Lee
Department of Pathology
Ajou University School of Medicine
164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499, Republic of
Korea
J.-S. Roe
Department of Biochemistry
College of Life Science and Biotechnology
Yonsei University
Seoul 03722, Republic of Korea
Y. Lee
Institute of Medical Science
Ajou University School of Medicine
164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499, Republic of
Korea
S.-M.H. and Y.-J.H. contributed equally to this work.
*Corresponding author.
Abstract
Receptor-interacting protein kinase 3 (RIPK3) is the primary regulator of necroptotic cell death. RIPK3 expression is often silenced in various cancer cells, which suggests that it may have tumor suppressor properties. However, the exact mechanism by which RIPK3 negatively regulates cancer development and progression remains unclear. This report indicates that RIPK3 acts as a potent regulator of the homeostatic proliferation of CD4+CD8+ double-positive (DP) thymocytes. Abnormal proliferation of RIPK3-deficient DP thymocytes occurs independently of the well-known role for RIPK3 in necroptosis (upstream of MLKL activation), and is associated with an incidental thymic mass, likely thymic hyperplasia. In addition, Ripk3-null mice develop increased thymic tumor formation accompanied by reduced host survival in the context of an N-ethyl-N-nitrosourea (ENU)-induced tumor model. Moreover, RIPK3 deficiency in p53-null mice promotes thymic lymphoma development via upregulated extracellular signal-regulated kinase (ERK) signaling, which correlates with markedly reduced survival rates. Mechanistically, lymphocyte-specific protein tyrosine kinase (LCK) activates RIPK3, which in turn leads to increases in the phosphatase activity of protein phosphatase 2 (PP2A), thereby suppressing hyper-activation of ERK in DP thymocytes. Overall, these findings suggest that a RIPK3-PP2A-ERK signaling axis regulates DP thymocyte homeostasis and may provide a potential therapeutic target to improve thymic lymphoma therapies.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기